Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Pyridorin in Patients With Diabetic Nephropathy

This study has been completed.
Information provided by:
BioStratum Identifier:
First received: April 27, 2006
Last updated: NA
Last verified: April 2006
History: No changes posted

The primary objective of the study is to evaluate the safety and tolerability of Pyridorin (pyridoxamine dihydrochloride) 50 mg given orally twice daily in patients with diabetic kidney disease.

Condition Intervention Phase
Diabetic Nephropathy
Drug: Pyridorin (pyridoxamine dihydrochloride)
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, 24-Week Study to Evaluate the Safety and Tolerability of Pyridorin (Pyridoxamine Dihydrochloride) in Patients With Diabetic Nephropathy Associated With Type 1 or Type 2 Diabetes

Resource links provided by NLM:

Further study details as provided by BioStratum:

Estimated Enrollment: 128
Study Start Date: October 2001
Estimated Study Completion Date: January 2003

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Males and Females (non-pregnant and non-lactating) between 18 and 70 years of age with type 1 or type 2 diabetes
  • Sitting blood pressure of <=170/100 mm Hg at weeks -2 and -1
  • Hemoglobin A1C <=12% at week -2
  • Patients with diagnosis of diabetic nephropathy as defined by

    1. Serum Creatinine <=2.0 mg/dL at weeks -2 and -1
    2. Urinary albumin excretion >=300 mg/24 hours at week -2
    3. Diagnosis of diabetic retinopathy
  • Creatinine clearance >=40 mL/min at weeks -2 and -1
  • Voluntary written consent to participate in this study

Exclusion Criteria:

  • History of allergic or adverse response to any B vitamin
  • History of major cardiovascular or cerebrovascular events
  • History of cancer except adequately treated basal or squamous cell carcinoma of the skin
  • History of diabetic ketoacidosis
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00320060

Sponsors and Collaborators
Study Director: Thorsten P Degenhardt, Ph.D. BioStratum, Inc.
  More Information

No publications provided Identifier: NCT00320060     History of Changes
Other Study ID Numbers: PYR-206
Study First Received: April 27, 2006
Last Updated: April 27, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by BioStratum:
Diabetic nephropathy
Advanced Glycation Endproduct Inhibitor

Additional relevant MeSH terms:
Diabetic Nephropathies
Kidney Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases
Urologic Diseases
Growth Substances
Pharmacologic Actions
Physiological Effects of Drugs
Vitamin B Complex
Vitamins processed this record on November 20, 2014